Taking the fight to their realm: the role of patent oppositions in the struggle for access to medicines.
When it amended its patent laws in 2005, in accordance with the TRIPS (Trade-related Aspects of Intellectual Property Rights) agreement, India was forced to recognize a 20-year period of patent protection for pharmaceuticals, placing the continued ability of Indian generic companies to manufacture affordable antiretroviral drugs (ARVs) in jeopardy. In this article, which is based on a presentation at an abstract-driven session at the conference, Chan Park discusses the successes and challenges experienced by Indian health groups in their novel efforts to oppose the granting of patents for critical drugs.
Park
Chan
C
D019380:Anti-HIV Agents / Q000600:supply & distribution* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D006297:Health Services Accessibility; D006801:Humans; D010330:Patents as Topic
D019380:Anti-HIV Agents